Cargando…

1728. Immune Responses to Cross-Reactive Serotypes 6C and 15C After 20-Valent Pneumococcal Conjugate Vaccine in Infants

BACKGROUND: The 20-valent pneumococcal conjugate vaccine (PCV20) was developed to expand protection against pneumococcal disease. PCV20 contains conjugates for serotype 6A, which is also in 13-valent PCV (PCV13) and appears to have had a clinical impact on 6C disease, and the additional serotype 15B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tamimi, Noor, Kline, Mary J, Center, Kimberly J, Thompson, Allison, Baugher, Gary, Drozd, Jelena, Scully, Ingrid L, Giardina, Peter, Trammel, James, Lei, Lanyu, Peng, Yahong, Scott, Daniel, Gruber, William C, Watson, Wendy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679186/ http://dx.doi.org/10.1093/ofid/ofad500.1560

Ejemplares similares

1944. Tolerability and Safety of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Infants and Older Children in Global Studies
por: Flint, Laurence, et al.
Publicado: (2023)

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2021)

1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2020)

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial
por: Simon, Michael W., et al.
Publicado: (2023)

The 15-valent pneumococcal conjugate vaccine V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
por: Patel, Sweta M., et al.
Publicado: (2022)

Carrier-Induced Hyporesponsiveness to Pneumococcal Conjugate Vaccines: Unraveling the Influence of Serotypes, Timing, and Previous Vaccine Dose
por: Dagan, Ron, et al.
Publicado: (2020)

Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use
por: Baxter, Roger, et al.
Publicado: (2020)

Periodic cycles of pneumococcal serotypes carried by children before and after 7-valent pneumococcal conjugate vaccine
por: Paulo, Ana Cristina, et al.
Publicado: (2017)

Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
por: Hanquet, Germaine, et al.
Publicado: (2022)

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations
por: Juergens, Christine, et al.
Publicado: (2018)

2707. Non 13-Valent Pneumococcal Conjugate Vaccine Serotypes Predominate as Causes of Pneumococcal Otitis Media in Children
por: Hulten, Kristina G, et al.
Publicado: (2019)

Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA
por: Owusu-Edusei, Kwame, et al.
Publicado: (2022)

P06 The 15-valent pneumococcal conjugate vaccine (PCV) V114 induces cross-reactive antibodies against pneumococcal serotype 6C
por: Shi, Yaru, et al.
Publicado: (2023)

Serotype-specific effectiveness against pneumococcal carriage and serotype replacement after ten-valent Pneumococcal Conjugate Vaccine (PCV10) introduction in Pakistan
por: Nisar, Muhammad Imran, et al.
Publicado: (2022)

Correction to: Estimates of the Health and Economic Burden of Pneumococcal Infections Attributable to the 15-Valent Pneumococcal Conjugate Vaccine Serotypes in the USA
por: Owusu-Edusei, Kwame, et al.
Publicado: (2022)

Clonal Expansion within Pneumococcal Serotype 6C after Use of Seven-Valent Vaccine
por: Loman, Nicholas J., et al.
Publicado: (2013)

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015)

16. A Randomized Phase 1 Study of a Novel Pneumococcal Conjugate Vaccine in Healthy Japanese Adults in the United States
por: Fitz-Patrick, David, et al.
Publicado: (2020)

Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001
por: Leach, Amanda J, et al.
Publicado: (2009)

576. Burden of Pneumococcal Disease Due to Serotypes Covered by the 13-Valent and New Higher-Valent Pneumococcal Conjugate Vaccines in All Children and Children at Risk in the United States
por: Huang, Liping, et al.
Publicado: (2022)

Systematic Literature Review of the Epidemiological Characteristics of Pneumococcal Disease Caused by the Additional Serotypes Covered by the 20-Valent Pneumococcal Conjugate Vaccine
por: Méroc, Estelle, et al.
Publicado: (2023)

Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong
por: Mohanty, Salini, et al.
Publicado: (2022)

A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States
por: Fitz-Patrick, David, et al.
Publicado: (2021)

Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly
por: Kislaya, Irina, et al.
Publicado: (2019)

Serotype-Specific IgG Antibody Waning after Pneumococcal Conjugate Primary Series Vaccinations with either the 10-Valent or the 13-Valent Vaccine
por: van Westen, Els, et al.
Publicado: (2018)

Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines
por: Ben-Shimol, Shalom, et al.
Publicado: (2021)

Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study
por: Cordonnier, Catherine, et al.
Publicado: (2015)

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
por: van Deursen, Anna M.M., et al.
Publicado: (2012)

1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age
por: Hurley, Donald, et al.
Publicado: (2020)

1446. Correlation Between Adult Invasive and Noninvasive Streptococcus pneumoniae Disease in 13-Valent Pneumococcal Conjugate Vaccine Serotypes in the United States
por: Suaya, Jose A, et al.
Publicado: (2018)

7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement?
por: Choi, Yoon Hong, et al.
Publicado: (2011)

Comparative Immunogenicity of 7 and 13-Valent Pneumococcal Conjugate Vaccines and the Development of Functional Antibodies to Cross-Reactive Serotypes
por: Grant, Lindsay R., et al.
Publicado: (2013)

Serotype Distribution of Clinical Streptococcus pneumoniae Isolates before the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Cambodia
por: Inghammar, Malin, et al.
Publicado: (2018)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
por: Gourzoulidis, George, et al.
Publicado: (2023)

3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older
por: Essink, Brandon, et al.
Publicado: (2020)

1100 Notable Serotype Replacement of Invasive Streptococcus pneumoniae in Kagoshima, Japan, after the Sequential Introduction of 7-valent and 13-valent Pneumococcal Conjugate Vaccines
por: Nishi, Junichiro, et al.
Publicado: (2014)

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years
por: Essink, Brandon, et al.
Publicado: (2021)

Prevalent Multidrug-resistant Nonvaccine Serotypes in Pneumococcal Carriage of Healthy Korean Children Associated with the Low Coverage of the Seven-valent Pneumococcal Conjugate Vaccine
por: Lee, Sungkyoung, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r921umi3b077413fl2h41uas6i